Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03598270

Recruitment Status : Active, not recruiting

First Posted : July 26, 2018

Last Update Posted : January 2, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Hoffmann-La Roche

GlaxoSmithKline

AGO Study Group

Belgian Gynaecological Oncology Group

ARCAGY/ GINECO GROUP

Israeli Society of Gynecologic Oncology

MaNGO

Apices Soluciones S.L.

Information provided by (Responsible Party):

Grupo Español de Investigación en Cáncer de Ovario

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	January 2024
Estimated Study Completion Date :	January 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gonzalez Martin A, Sanchez Lorenzo L, Colombo N, dePont Christensen R, Heitz F, Meirovitz M, Selle F, van Gorp T, Alvarez N, Sanchez J, Marques C. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. Int J Gynecol Cancer. 2021 Apr;31(4):617-622. doi: 10.1136/ijgc-2020-001633. Epub 2020 Dec 14.

To Top